Reshma Kewalramani bought $3.9M of VRTX
CEO & President at VERTEX PHARMACEUTICALS INC / MA. 10,000 shares at an average of $389.58, traded Aug 6, 2025, filed Aug 7, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.9M at market
- +3Relative to holdingsHoldings up 9%
- +14Price context3% above the 52-week low; 25% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.5%, 3m +10.8%, 6m +22.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-25-000220, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2025 | POpen-market purchase Common Stock | +4,290 | $389.08 | $1.7M | 110,258 | Aug 7, 2025 |
| Aug 6, 2025 | POpen-market purchase Common Stock | +5,710 | $389.95 | $2.2M | 115,968 | Aug 7, 2025 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | VERTEX PHARMACEUTICALS INC / MA | Duncan McKechnie EVP, Chief Commercial Officer | $800k 1,541 shares | -12% | |
| 32Weak | VERTEX PHARMACEUTICALS INC / MA | Ourania Tatsis EVP, Chief Reg. & Quality Off. | $787k 1,500 shares | -3% | |
| 26Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $416k 828 shares | -4% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $288k 596 shares | -4% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $471k 1,020 shares | -6% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.8M 4,062 shares | -19% | |
| 25Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $785k 1,745 shares | -8% | |
| 18Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $364k 828 shares | -4% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $888k 1,974 shares | -8% | |
| 30Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $614k 1,354 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.